At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Investors
 



Home >> Investor Relations >> SEC Filings

SEC Filings

  
Filing Description Date Filed Sorted Descending Size View  
EFFECT effectiveness order Jan 27, 2011 0.0 KB View HTML  
4 valenzano, ken Jan 20, 2011 24.4 KB View HTML View PDF View XLS  
4 schaeffer, orlov s nicole Jan 20, 2011 24.8 KB View HTML View PDF View XLS  
4 peist, kenneth Jan 20, 2011 24.4 KB View HTML View PDF View XLS  
4 patterson, matthew r Jan 20, 2011 24.8 KB View HTML View PDF View XLS  
4 lockhart, david j Jan 20, 2011 24.7 KB View HTML View PDF View XLS  
4 kirk, john Jan 20, 2011 24.7 KB View HTML View PDF View XLS  
4 gilmore, geoffrey Jan 20, 2011 24.7 KB View HTML View PDF View XLS  
4 dilone, enrique Jan 20, 2011 24.4 KB View HTML View PDF View XLS  
4 crowley, john f Jan 20, 2011 24.8 KB View HTML View PDF View XLS  
4 campbell, bradley l Jan 20, 2011 24.8 KB View HTML View PDF View XLS  
4 boudes, pol f Jan 20, 2011 24.7 KB View HTML View PDF View XLS  
3 dilone enrique Jan 19, 2011 23.9 KB View HTML View PDF View XLS  
3 peist kenneth Jan 19, 2011 25.9 KB View HTML View PDF View XLS  
8-K current report Jan 11, 2011 2.8 MB View HTML View PDF View XLS  
S-3 registration statement Jan 11, 2011 140.6 KB View HTML View PDF View XLS  
8-K current report Dec 21, 2010 96.4 KB View HTML View PDF View XLS  
3 glaxosmithkline plc Nov 16, 2010 21.2 KB View HTML View PDF View XLS  
10-Q quarterly report Nov 9, 2010 346.8 KB View HTML View PDF View XLS  
8-K current report Nov 8, 2010 79.2 KB View HTML View PDF View XLS  
Showing 161-180 of 638 Page: 1 ... 5 6 7 8 9 10 11 12 13 ... 32  Previous 20 | Next 20

Copyright © 2012 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy